Effects of single dose mixed amphetamine salts - extended release on processing speed in multiple sclerosis: a double blind placebo controlled study
- 458 Downloads
Multiple sclerosis (MS) commonly affects cognitive function, most frequently presenting as impaired processing speed (PS). There are currently no approved treatments for PS in this population, but previous studies suggest amphetamines may be beneficial.
The objective of this study is to determine if mixed amphetamine salts, extended release (MAS-XR) has the potential to improve impaired PS in MS patients in a randomized controlled pre- and post-dose testing study.
Fifty-two MS patients demonstrating PS impairment on either the Symbol Digit Modalities Test (SDMT) or Paced Auditory Serial Addition Test (PASAT) were randomized to a single dose of 5 mg MAS-XR (n = 18), 10 mg MAS-XR (n = 20), or placebo (n = 14). Subjects were evaluated a second time, after taking the blinded medication. ANOVA was used to compare the change on the SDMT and PASAT in each of the treatment groups compared to the placebo. Cohen’s d was used to calculate effect size.
At baseline, the mean SDMT score was 43.3 ± 7.2 and the mean PASAT was 34.8 ± 13.4, with 47 (90.4 %) and 25 (48.1 %) categorized as impaired on the SDMT and PASAT, respectively. The change in SDMT scores from baseline to post-treatment demonstrated significant improvement for the MAS-XR 10-mg dose compared to placebo, increasing by 5.2 ± 4.5 vs. 0.6 ± 4.4 points (p = 0.043), with a medium effect size of 0.47. Change on the PASAT was not significantly different in either treatment group.
This study supports MAS-XR 10 mg as a potential treatment for MS patients with demonstrated PS impairment, warranting a larger longitudinal study.
KeywordsMultiple sclerosis Randomized clinical trial Cognitive impairment Processing speed Amphetamine Treatment
Attention deficit hyperactivity disorder
Beck Depression Inventory-Fast Screen
Brief International Cognitive Assessment for MS
Brief Repeatable Neuropsychological Battery
Expanded Disability Status Scale
Fatigue Severity Scale
Minimal Assessment of Cognitive Function in MS
Mixed amphetamine salts, extended release
Multiple Sclerosis Functional Composite
Paced Auditory Serial Addition Test
Primary progressive multiple sclerosis
Relapsing remitting multiple sclerosis
Symbol Digit Modalities Test
Secondary progressive multiple sclerosis
Funding was provided by the Internal Research Fund (IRF), Department of Clinical Neurological Sciences, Western University.
Conflict of interest
The authors declare that they have no competing interests.
- Beatty WW, Blanco CR, Wilbanks SL, Paul RH (1995) Demographic, clinical, and cognitive characteristics of multiple sclerosis patients who continue to work. J Neurol Rehab 9:167–173Google Scholar
- Benedict RHB, Fischer JS, Archibald CJ, Arnett PA, Beatty WW, Bobholz J, Chelune G, Fisk JD, Langdon DW, Caruso LS, Foley FW, LaRocca NG, Vowels L, Weinstein A, DeLuca J, Rao SM, Munschauer FE (2002) Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol 16:381–397CrossRefPubMedGoogle Scholar
- Benedict RHB, Wahlig E, Bakshi R, Fishman I, MunschauerF, Zivadinov R, Weinstock-Guttman B (2005) Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci 1–2: 29–34Google Scholar
- Benedict RH, Duquin JA, Jurgensen S, Rudick RA, Feitcher J, Munschauer FE, Panzara MA, Weinstock-Guttman B (2008) Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler 14(7):940–946CrossRefPubMedGoogle Scholar
- Harel Y, Appleboim N, Lavie M, Achiron A (2008) Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. J Neurol Sci 276: 38–40Google Scholar
- Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hamalainen P, Hartung HP, Krupp L, Penner IK, Reder AT, Benedict RH (2012) Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 18(6):891–898PubMedCentralCrossRefPubMedGoogle Scholar
- Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH (2010a) Evaluation of the Symbol Digit Modalities Test (SDMT) and MS Neuropsychological Screening Questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler 16(11):1385–1392CrossRefPubMedGoogle Scholar
- Parmenter BA, Zivadinov R, Kerenyi L, Gavett R, Weinstock-Guttman B, Dwyer MG, Garg N, Munschauer F, Benedict RH (2007b) Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J Clin Exp Neuropsychol 29(2):215–223CrossRefPubMedGoogle Scholar
- Pharmaceuticals S (2011) Medication guide. Highlights of prescribing information. US Drug and Food Administration, WayneGoogle Scholar
- Rao SM (1991) A manual for the Brief Repeatable Battery of Neuropsychological Tests in multiple sclerosisGoogle Scholar
- Schweitzer JB, Lee DO, Hanford RB, Zink CF, Ely TD, Tagamets MA, Hoffman JM, Grafton ST, Kilts CD (2004) Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: normalization of behavior but not related brain activity. Biol Psychiatry 56(8):597–606CrossRefPubMedGoogle Scholar
- Smith A (1982) Symbol Digit Modalities Test: manual. Western Psychological Services, Los AngelesGoogle Scholar